Michael O'Riordan

Hamilton

Senior Journalist, Cardiovascular Research Foundation at TCTMD

Medical journalist with @TCTMD. Likes running marathons, baseball, and vegetarian food. Dislikes snow, flat (bike) tires, and stress fractures.

Featured in: Favicon

tctmd.com

medscape.com Favicon

newsbreak.com Favicon

thetablet.co.uk Favicon

etfstream.com Favicon

ourcommunitynow.com

Articles

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

1 week ago | tctmd.com | Michael O'Riordan

News Conference News EuroPCR 2025 The findings hint at why the AβYSS trial failed to show it was safe to stop beta-blockers after an MI in stable patients. PARIS, France—Patients with myocardial infarction and preserved LVEF who stop their beta-blocker have significant rises in heart rate and blood pressure that appear to increase the likelihood of adverse outcomes, particularly among those with hypertension, an analysis of the AΒYSS trial shows.
Tendyne Approved in US for High-risk Patients With Mitral Valve Disease

1 week ago | tctmd.com | Michael O'Riordan

The approval is tightly defined: the system will be for patients ineligible for surgery and with anatomy unfavorable for TEER. The US Food and Drug Administration has approved the Tendyne transcatheter mitral valve replacement (TMVR) system for the treatment of patients with mitral valve dysfunction, device manufacturer Abbott announced today.
Underexpanded Acurate neo2 Valves Tied to Worse Outcomes: ACURATE IDE

1 week ago | tctmd.com | Michael O'Riordan

News Daily News EuroPCR 2025 This factor helps explain why the device failed to match other commercially approved devices in the IDE trial. PARIS, France—More than one in five Acurate neo2 transcatheter heart valves (Boston Scientific) implanted in patients as part of the ACURATE investigational device exemption (IDE) study were underexpanded, a new analysis shows. In these cases, patients fared significantly worse compared with those with a fully opened valve.
Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

2 weeks ago | tctmd.com | Michael O'Riordan

News Conference News EuroPCR 2025 The higher stroke risk appears to accrue over time, and researchers say more work is needed to better understand why. PARIS, France—New mid-term data from the United Kingdom raise some concern about a heightened risk of stroke among patients with severe aortic stenosis treated with TAVI versus those who underwent surgical aortic valve replacement.
Higher Mortality With TAVI Over Surgery in Bicuspid Aortic Stenosis

2 weeks ago | tctmd.com | Michael O'Riordan

News Conference News EuroPCR 2025 Once again, data are suggesting that operators should move cautiously in bicuspid anatomy and think about surgery first. PARIS, France—There is more than a twofold greater risk of death, and a significantly increased risk of major adverse cardiac events, over nearly 2 years of follow-up when patients with a bicuspid aortic valve undergo TAVI instead of surgery for severe aortic stenosis, a new analysis suggests.
Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

2 weeks ago | tctmd.com | Michael O'Riordan

News Conference News EuroPCR 2025 With the new analysis, researchers rule out embolic protection for stroke prevention in TAVI, but not everybody has given up. PARIS, France—A new analysis of more than 10,000 patients likely slams the door on routinely using cerebral embolic protection for stroke prevention in patients with aortic stenosis undergoing TAVI.
Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

2 weeks ago | tctmd.com | Michael O'Riordan

A decade on, there’s less revascularization with FFR-guided complete vs culprit only PCI, but COMPLETE-2 is on the way. PARIS, France—Complete revascularization guided by fractional flow reserve (FFR) remains superior to treating just the culprit lesion more than a decade on in STEMI patients with multivessel disease, a long-term analysis of DANAMI-3-PRIMULTI shows.
Higher CVD Risk in Children as Young as 10 Who Have Central Adiposity

3 weeks ago | tctmd.com | Michael O'Riordan

News Conference News European Congress on Obesity 2025 At this early age, metabolism is already dysregulated and lifestyle changes are warranted to prevent future disease. MALAGA, Spain—Children with growing waistlines are more likely to show signs of increased cardiovascular and metabolic risk by the time they reach 10 years of age, an observational analysis shows.
Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

3 weeks ago | tctmd.com | Michael O'Riordan

News Conference News European Congress on Obesity 2025 When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed.
SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

3 weeks ago | tctmd.com | Michael O'Riordan

News Conference News European Congress on Obesity 2025 The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients. MALAGA, Spain—Clinicians caring for patients with obesity or overweight and established cardiovascular disease should start patients on semaglutide (Wegovy; Novo Nordisk) as soon as possible.